uploads/2018/11/Arrowhead.png

Arrowhead Pharmaceuticals Stock Has Risen ~252% Year-to-Date

By

Updated

ARWR’s performance

On November 21, Arrowhead Pharmaceuticals (ARWR) stock closed at $12.95, a ~5.28% rise from its previous day’s close of $12.30. Arrowhead Pharmaceuticals stock rose from $3.68 at the close of market on December 29, 2017, to $12.95 at the close of market on November 21, 2018, a ~252% rise year-to-date.

On November 21, Arrowhead Pharmaceuticals closed at $12.95, ~42% below the 52-week high of $22.39 it reached on September 6. Arrowhead Pharmaceuticals hit its 52-week low of $3.01 on December 13, 2017.

Article continues below advertisement

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals is focused on the development of therapies for the treatment of intractable diseases via the gene silencing of the genes that cause the disease. Arrowhead Pharmaceuticals recently presented preclinical data for its two cardiometabolic drug candidates, ARO-APOC3 and ARO-ANG3.

The company has completed enrolment and dosing of the Phase 1/2 trial of ARO-HBV for the evaluation of its safety and efficacy parameters in the treatment of individuals with hepatitis B.

Financials in a nutshell

Arrowhead Pharmaceuticals’ net revenue in the first nine months of 2018 amounted to $4.9 million compared to $22.7 million in the same period of the previous year. Arrowhead’s biopharmaceutical peers Dicerna Pharmaceuticals (DRNA) and Regenxbio (RGNX) generated revenues of $1.5 million and $5.3 million, respectively, in the third quarter compared to $0.47 million and $1.3 million, respectively, in the third quarter of 2017.

Arrowhead Pharmaceuticals’ research and development and general and administrative expenses in the first nine months of the year amounted to $37.0 million and $12.7 million, respectively, compared to $37.4 million and $12.1 million, respectively, in the same period of the previous year.

Arrowhead Pharmaceuticals reported net income and diluted EPS of -$43.7 million and -$0.53, respectively, compared to net income and diluted EPS of -$13.4 million and -$0.32, respectively, in the same period of the previous year.

Analysts’ recommendations

Of the six analysts tracking Arrowhead Pharmaceuticals in November, two have recommended “strong buys,” and four have recommended “holds” on the stock.

On November 22, Arrowhead Pharmaceuticals had a consensus 12-month target price of $23.3 which represents a potential ~79.92% return on investment over the next 12 months.

Advertisement

More From Market Realist